Home/Filings/4/0001209191-18-007472
4//SEC Filing

Powala Christopher 4

Accession 0001209191-18-007472

CIK 0001557746other

Filed

Feb 4, 7:00 PM ET

Accepted

Feb 5, 4:22 PM ET

Size

8.0 KB

Accession

0001209191-18-007472

Insider Transaction Report

Form 4
Period: 2018-02-01
Powala Christopher
Chief Operating Officer
Transactions
  • Award

    Stock option (right to buy)

    2018-02-01+47,60047,600 total
    Exercise: $22.09Exp: 2028-01-31Common Stock (47,600 underlying)
  • Award

    Restricted stock units

    2018-02-01+13,60013,600 total
    Common Stock (13,600 underlying)
Footnotes (3)
  • [F1]The option will vest over a period of four years, with 25% of the shares underlying the option vesting on the first, second, third and fourth anniversaries of the date of grant.
  • [F2]Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
  • [F3]The shares underlying these restricted stock units vest in four equal annual installments beginning on February 1, 2019, subject to the reporting person's continuous service with the issuer as of the applicable vesting date.

Issuer

Aclaris Therapeutics, Inc.

CIK 0001557746

Entity typeother

Related Parties

1
  • filerCIK 0001654301

Filing Metadata

Form type
4
Filed
Feb 4, 7:00 PM ET
Accepted
Feb 5, 4:22 PM ET
Size
8.0 KB